Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S
Department of Radiology, Lainz Hospital, Vienna, Austria.
Anticancer Res. 2000 Jan-Feb;20(1B):553-8.
We aimed to assess the mammographic features of locally advanced breast carcinoma treated with neoadjuvant chemotherapy and to evaluate morphological criteria that determine the value of mammography in therapy monitoring.
We reviewed the pre- and post-therapeutic mammograms of 44 patients with stage III-breast carcinoma with regard to tumor characteristics and malignant calcifications and compared to histopathological results.
Delineation of the tumor proved to be the most significant criterion. In 34 tumors more than 50% of the lesion was defined; these showed a high correlation between the mammographically determined tumor diameter and that determined on histopathological examination (r = 0.77). Less than 50% of the mass was definable in 14 tumors; here the correlation between mammographically and histopathologically determined tumor diameter was low (r = -0.19).
The diagnostic value of mammography in the evaluation of tumor response to induction chemotherapy depends primarily on the extent to which the tumor can be delineated from the adjacent breast tissue. For tumors whose margins can be defined by more than 50% on the baseline mammogram, the diagnostic reliability of mammography is high. Ill-defined masses should preferably be assessed with other imaging procedures such as ultrasonography or magnetic resonance imaging.
我们旨在评估接受新辅助化疗的局部晚期乳腺癌的乳腺钼靶特征，并评估决定乳腺钼靶在治疗监测中价值的形态学标准。
我们回顾了44例III期乳腺癌患者治疗前和治疗后的乳腺钼靶片，观察肿瘤特征和恶性钙化情况，并与组织病理学结果进行比较。
肿瘤轮廓的显示被证明是最重要的标准。在34个肿瘤中，超过50%的病变可被界定；这些肿瘤在乳腺钼靶测定的肿瘤直径与组织病理学检查测定的肿瘤直径之间显示出高度相关性（r = 0.77）。在14个肿瘤中，可界定的肿块小于50%；在此情况下，乳腺钼靶和组织病理学测定的肿瘤直径之间的相关性较低（r = -0.19）。
乳腺钼靶在评估诱导化疗的肿瘤反应中的诊断价值主要取决于肿瘤与相邻乳腺组织的可界定程度。对于在基线乳腺钼靶片上边缘可被界定超过50%的肿瘤，乳腺钼靶的诊断可靠性较高。边界不清的肿块最好用其他成像检查方法，如超声或磁共振成像进行评估。
